In about 73% of the cases of advanced cancer, MMP-1 immunoreactivity was associated significantly with peritoneal metastasis and lymph-node metastasis, as well as with worse survival in comparison to MMP-1-negative gastric cancer [75]. This evidence concerns the gene MMP1 and metastatic malignant neoplasm in the lymph nodes.